Phillip S.Beck

Associate

San Diego + 1.858.314.1165

Phillip Beck represents a wide range of clients in intellectual property disputes across multiple venues, including before district courts, the Patent Trial and Appeal Board, the U.S. International Trade Commission, and the Court of Appeals for the Federal Circuit.

Phillip was part of a trial team that won a patent infringement case brought under the Biologics Price Competition and Innovation Act (BPCIA) related to one of the first, and most successful, biologic drugs. He has represented pharmaceutical and consumer electronics companies in inter partes reviews (IPRs) and in appeals to the Federal Circuit. Phillip has also represented a major consumer electronics company in FRAND (fair, reasonable, and non-discriminatory) litigation.

As an undergraduate student at Brigham Young University, Phillip spent two years as a histologist in an on-campus research lab investigating the biomolecular etiology and pathophysiology of osteoarthritis, using murine genetic and surgical osteoarthritis models.

Phillip is a member of the San Diego Intellectual Property Law Association.

Experience

  • Merck unit files DJ action involving pneumococcal vaccine patentsJones Day is representing Merck Sharp & Dohme Corp. in an action in Delaware district court against Wyeth, LLC seeking declaratory judgment of invalidity and non-infringement of U.S. patent Nos. 8,895,024; 8,808,708 and 9,399,060 relating to a new 15-valent pneumococcal conjugate vaccine, known as V114, for the prevention of invasive pneumococcal disease in adults 18 years of age and older.
  • Allergan defends JUVEDERM® patents against nine IPR petitions filed by ProlleniumJones Day is representing Allergan, Inc. before the U.S. Patent Trial and Appeal Board ("PTAB") on nine IPR petitions filed by Prollenium challenging multiple patents covering certain of Allergan's JUVEDERM® products, hyaluronic acid-based dermal fillers that include the anesthetic lidocaine.
  • The following represents experience acquired prior to joining Jones Day.

    Represented a major pharmaceutical company in district court litigation brought under BPCIA related to one of the first, and most successful, antibody-related therapeutics. Served on the trial team that won judgment of infringement and validity.

    Represented a major pharmaceutical company in prelitigation diligence of patent portfolio related to antibodies that modulate an immune checkpoint inhibitor as an oncological therapeutic.

    Represented a pharmaceutical company in prelitigation diligence of patent portfolio related to third-generation (two co-stimulatory domain) CAR-T immuno-oncological therapeutic.

    Represented a major memory semiconductor manufacturer and supplier in appeals from Patent Trial and Appeal Board inter partes review proceedings to the Court of Appeals for the Federal Circuit.

    Represented a major pharmaceutical company in inter partes review proceedings related to small molecule HIV infection treatments.

    Represented a major pharmaceutical company in inter partes review proceedings defending validity of patent related to techniques for improving the expression of antibodies.

    Represented a major pharmaceutical company in prelitigation diligence of patent portfolio related to antibody/small molecule combination therapy for HIV infection.

    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.